Timber Hill’s Vertex Pharmaceuticals VRTX Stock Holding History

Timber Hill’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-14,900	Closed	-$1.63M	–	1830
2017 Q1	$1.63M	Buy	14,900 +2,300	+18%	+$202K	0.01%	804
2016 Q4	$928K	Buy	+12,600	New	+$1.03M	﹤0.01%	1308
2016 Q1	–	Sell	-3,800	Closed	-$478K	–	2354
2015 Q4	$478K	Sell	3,800 -28,400	-88%	-$3.43M	﹤0.01%	1723
2015 Q3	$3.35M	Buy	32,200 +17,000	+112%	+$2.18M	0.01%	736
2015 Q2	$1.88M	Buy	15,200 +7,900	+108%	+$995K	0.01%	1104
2015 Q1	$861K	Sell	7,300 -10,900	-60%	-$1.31M	﹤0.01%	1498
2014 Q4	$2.16M	Sell	18,200 -1,600	-8%	-$180K	0.01%	991
2014 Q3	$2.22M	Sell	19,800 -8,200	-29%	-$781K	0.01%	1078
2014 Q2	$2.65M	Sell	28,000 -17,200	-38%	-$1.21M	0.01%	991
2014 Q1	$3.2M	Sell	45,200 -200	-0.4%	-$15.8K	0.01%	868
2013 Q4	$3.37M	Sell	45,400 -4,800	-10%	-$334K	0.01%	1015
2013 Q3	$3.81M	Sell	50,200 -72,200	-59%	-$5.75M	0.01%	1027
2013 Q2	$9.8M	Buy	+122,400	New	+$9.01M	0.04%	449

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Timber Hill's VRTX Position: Q2 2018 in Review

Timber Hill sold out of Vertex Pharmaceuticals (VRTX) in Q2 2018, closing a stake of 6,405 shares — an estimated $1.04M sold.

Timber Hill first reported a position in VRTX in Q3 2013 and held it in 5 quarters. The position peaked at $1.79M in Q2 2014. 690 funds tracked by Wall St. Rank hold VRTX as of Q2 2018.

Timber Hill reported no remaining Vertex Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Timber Hill sold 6,405 Vertex Pharmaceuticals shares in Q2 2018, an estimated $1.04M.
Timber Hill first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 5 quarters.
Timber Hill's Vertex Pharmaceuticals position peaked at $1.79M in Q2 2014.
690 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2018.

Based on Timber Hill's 13F filing for Q2 2018, filed 9 Aug 2018.